At the end of week 1, you meet FDA target
71% of MPC-treated patients who achieved ACR20 responses did so as early as week 1
At week 12 your drug exceeds it and placebo goes nowhere
At week 12, 27% of MPC-treated patients, but no placebo-treated controls, achieved ACR50 or ACR 70 responses
At this LOW dose, 20% of patients show remission
Remission at week 12, as defined by Disease Activity Score (DAS28/CRP) <2.6, was seen in 20% of MPC-treated patients but in no controls.
These are the least responsive group of patients they could find and they got a good result
GLTAH
Ann: MSB Therapy Shows Benefit In First Cohort Of RA Patients, page-4
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |